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Background: The potential for the human gut microbiota to serve as a reservoir for antibiotic resistance genes has
been the subject of recent discussion. However, this has yet to be investigated using a rapid PCR-based approach. In
light of this, here we aim to determine if degenerate PCR primers can detect aminoglycoside and β-lactam resistance
genes in the gut microbiota of healthy adults, without the need for an initial culture-based screen for resistant isolates.
In doing so, we would determine if the gut microbiota of healthy adults, lacking recent antibiotic exposure, is a
reservoir for resistance genes.
Results: The strategy employed resulted in the identification of numerous aminoglycoside (acetylation, adenylation
and phosphorylation) and β-lactam (including blaOXA, blaTEM, blaSHV and blaCTX-M) resistance gene homologues. On the
basis of homology, it would appear that these genes originated from different bacterial taxa, with members of the
Enterobacteriaceae being a particularly rich source. The results demonstrate that, even in the absence of recent
antibiotic exposure, the human gut microbiota is a considerable reservoir for antibiotic resistance genes.
Conclusions: This study has demonstrated that the gut can be a significant source of aminoglycoside and β-lactam
resistance genes, even in the absence of recent antibiotic exposure. The results also demonstrate that PCR-based
approaches can be successfully applied to detect antibiotic resistance genes in the human gut microbiota, without
the need to isolate resistant strains. This approach could also be used to rapidly screen other complex environments
for target genes.
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Almost as soon as the widespread therapeutic use of
antibiotics occurred, bacteria displaying diverse and
complex mechanisms of resistance became problematic
[1,2]. As the human gut is one of the most densely popu-
lated microbial environments, it has been postulated that
it can act as a considerable reservoir for antibiotic resistance
genes [3]. Thus, gut microbes may disseminate antibiotic
resistance genes to other commensals or to bacteria tran-
siently colonising the gut [4]. Given that antibiotics are
known to exert significant and sustained negative effects on
the gut microbiota [5,6], possessing resistance genes can
provide a significant selective advantage to a subpopulation* Correspondence: paul.cotter@teagasc.ie
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reproduction in any medium, provided the orof microorganisms in individuals undergoing antibiotic
treatment [7]. The aminoglycosides and β-lactams are two
large families of antibiotics which are frequently employed
in clinical settings. The aminoglycosides, which were first
characterised in 1944, [8] function by binding to the 30S
subunit of the prokaryotic ribosome resulting in disruption
to protein synthesis. Resistance to aminoglycosides can
be through reduced aminoglycoside uptake or enzymatic
modification of the aminoglycoside through acetylation
(AAC), adenylation (ANT) or phosphorylation (APH).
β-lactam antibiotics include the penicillins and cephalo-
sporins and inhibit bacteria through disruption of cell wall
biosynthesis [9,10]. Resistance to β-lactams can be due to
alterations to penicillin binding proteins or to the porins
in the outer membrane (in Gram negative targets) or
alternatively through the production of β-lactamases,Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the antibiotic inactive [11,12].
The question of the evolutionary origin of antibiotic
resistance genes has been the subject of much attention
[9,13,14]. For quite some time it was thought that resistance
evolved following exposure of bacteria to new antibiotics
[15]. However, it is now apparent that repositories of
antibiotic resistance genes exist such that, following the
development and application of new antibiotics, bacteria
possessing or acquiring such genes will gain a selective
advantage and thus resistance will increase over time
[16,17]. Previous studies have employed PCR to detect
resistance genes in specific pathogens [18,19], though
studies employing PCR to detect resistance genes in
complex microbial environments have been limited. In one
instance, a PCR-based approach was used to investigate the
prevalence of gentamycin resistance genes in resistant
isolates from sewage, faeces (from cattle and chickens),
municipal and hospital sewage water and coastal water
[20]. The utilisation of a PCR approach in that instance
resulted in the identification of diverse genes encoding
gentamycin modifying enzymes from across a broad host
range, thus demonstrating the suitability of a PCR-based
approach to investigate resistance genes present in com-
plex environments. However, the study did not investigate
antibiotic resistance genes in human gut microbiota and,
to our knowledge, to date no such PCR-based studies
exist. Given these findings and other indications that there
exist large natural pools of antibiotic resistance genes
within complex microbial populations, it is likely that
the human gut also contains many such genes. However,
until now, PCR-based strategies to detect antibiotic resist-
ance genes in the gut microbiota have involved an initial
culture-based screen for resistant isolates, followed by sub-
sequent PCR-based approaches to identify the associated
resistance genes. This does not take into consideration the
fact that the vast majority of gut microbes are not easily
cultured [21], and thus antibiotic resistance genes from
such microorganisms would typically be overlooked.
Here we utilise degenerate PCR primers to investigate
the presence of β-lactam resistance genes and each of the
three categories of aminoglycoside modifying enzymes
within human metagenomic DNA and in doing so dem-
onstrate that the human gut microbiota is a reservoir
for antibiotic resistance genes. Additionally, we establish
that a PCR-based approach allows the rapid detection of
such genes in the complex gut microbiota environment,
without the need for an initial isolation of strains.
Methods
Recruitment of volunteers
Forty adults were recruited and each provided written,
informed consent for participation in this study. Approval
for this trial was received from the Clinical ResearchEthics Committee of the Cork Teaching Hospitals, Cork,
Ireland. Volunteers were aged 28.8 ± 3.8 years, were free
from gastrointestinal disorders and had not been treated
with antibiotics in the 6 months prior to sample collection.
Fresh faecal samples were collected and stored at −80°C
until processed.
DNA extraction
Stool samples were weighed, homogenised and due to
the total volume provided by each individual, samples
had to be pooled to achieve the required volume for our
metagenomic DNA extraction protocol. To facilitate this,
an equal volume (250 mg) from each individual was taken
and pooled to form one sample, from which metagenomic
DNA was extracted. The DNA extraction procedure used
was optimised for total bacterial genomic DNA extraction
from stool samples. The stool sample was homogenized in
PBS and centrifuged at 1000 g × 5 mins and the super-
natant was removed and retained. This was repeated 3
times. The supernatant then underwent Nycodenz (Axis
Shield, UK) density gradient centrifugation separation, to
separate out the bacterial cells from faecal matter. Follow-
ing enzymatic lysis of bacterial cells using lysozyme and
mutanolysin (Sigma Aldrich, Dublin, Ireland) protein
precipitation using Proteinase K and ammonium acetate
(Sigma Aldrich) was completed. Bacterial DNA was then
precipitated and washed using standard chloroform and
ethanol procedures. DNA was eluted in TE buffer.
PCR-based detection of β-lactam resistance gene
homologues
PCR-based detection of β-lactam resistance genes was
completed using primers (MWG Eurofins, Germany) for
the genes blaTEM [22,23], blaSHV [24] (both of which are
classified as Bush group 2b β-lactamases), blaCTX-M [25]
(an extended spectrum β-lactamase (ESBL) which confers
resistance to cefotaxime), blaOXA [24] (ESBL, Bush group
2d ESBL) and blaROB [23] (confers high level ampicillin re-
sistance) (Table 1). PCRs were completed using bacterial
metagenomic DNA and all PCRs were performed in tripli-
cate. PCRs were completed on a G-storm PCR machine
and for the primer sets blaTEM primer set 1 (RH605/606),
blaTEM primer set 2 and blaCTX-M, PCRs were completed
as previously outlined. For the primers blaOXA and blaROB
the PCR conditions were as follows: heated lid 110°C,
94°C × 5 mins followed by 30 cycles of 94°C × 30s, 64°C ×
30s (blaoxa) or 62°C (blaROB) and 72°C × 30s followed by
72°C × 10 mins and held at 4°C. For blaSHV PCRs were
performed as follows: heated lid 110°C, 94°C × 5 mins
followed by 35 cycles of 94°C × 30s, 58°C × 30s and
72°C × 30s followed by a final extension step of 72°C × 10
mins and held at 4°C. All PCRs contained 25 μl Biomix
Red (Bioline, UK), 1 μl forward primer (10pmol con-
centration), 1 μl reverse primer (10pmol concentration),
Table 1 Primers used for the detection of β-lactamase and aminoglycoside resistant genes
Location Primer Sequence 5′-3′ Amplicon Size (bp) Annealing Temp°C Source
β-lactamase genes
BlaTEM RH605 TTTCGTGTCGCCCTTATTCC 692 60 Bailey et al. (2011) [22]
RH606 CCGGCTCCAGATTTATCAGC
Bla_TEMF TGGGTGCACGAGTGGGTTAC 526 57 Tenover et al. (1994) [23]
Bla_TEMR TTATCCGCCTCCATCCAGTC
BlaROB Bla_ROBF ATCAGCCACACAAGCCACCT 692 62 Tenover et al. (1994) [23]
Bla_ROBR GTTTGCGATTTGGTATGCGA
BlaSHV Bla_SHVF CACTCAAGGATGTATTGTG 885 58 Briñas et al. (2002) [24]
Bla_SHVR TTAGCGTTGCCAGTGCTCG
BlaOXA Bla_OXAF TTCAAGCCAAAGGCACGATAG 702 64 Briñas et al. (2002) [24]
Bla_OXAR TCCGAGTTGACTGCCGGGTTG
BlaCTX-M Bla_CTX-MF CGTTGTAAAACGACGGCCAGTGAATGTGCAGYACCAGTAARGTKATGGC 600 55 Monstein et al. (2009) [25]
Bla_CTX-MR TGGGTRAARTARGTSACCAGAAYCAGCGG
AG resistant genes
aac (3)-I Faac3-1 TTCATCGCGCTTGCTGCYTTYGA 239 58 Heuer et al. (2002) [20]
Raac3-1 GCCACTGCGGGATCGTCRCCRTA
aac (3)-II/VI Faac3-2 GCGCACCCCGATGCMTCSATGG 189 58
Raac3-2 GGCAACGGCCTCGGCGTARTGSA
Facc3-6 GCCCATCCCGACGCATCSATGG
Raac3-6 CGCCACCGCTTCGGCATARTGSA
aac (6′)-II/Ib Faac6 CACAGTCGTACGTTGCKCTBGG 235 58
Raac6 CCTGCCTTCTCGTAGCAKCGDAT
ant (2′)-I Fant TGGGCGATCGATGCACGGCTRG 428 58
Rant AAAGCGGCACGCAAGACCTCMAC
aph (2″)-I Faphc CCCAAGAGTCAACAAGGTGCAGA 527 55
Faphd GGCAATGACTGTATTGCATATGA 572 55
Raph GAATCTCCAAAATCRATWATKCC
aac (6′)-Ie-aph (2″)-Ia aac-aphF GAGCAATAAGGGCATACCAAAAATC 505 47 De Fatίma Silva Lopes et al. (2003) [26]
aac-aphR CCGTGCATTTGTCTTAAAAAACTGG
aac6-aph2F CCAAGAGCAATAAGGGCATACC 222 55 Schmitz et al. (1999) [27]
aac6-aph2R CACACTATCATAACCATCACCG
AG: aminoglycoside. Type of gene i.e. beta-lactamase or AG given in bold.
Fouhy
et
al.BM
C
M
icrobiology
2014,14:25
Page
3
of
10
http://w
w
w
.biom
edcentral.com
/1471-2180/14/25
Fouhy et al. BMC Microbiology 2014, 14:25 Page 4 of 10
http://www.biomedcentral.com/1471-2180/14/25metagenomic DNA (64 ng) and PCR grade water (Bioline,
UK), to a final volume of 50 μl. Negative controls were
completed for all primer sets. Gel electrophoresis was
performed on all samples using 1.5% agarose gel in 1× TAE
buffer.
PCR-based detection of aminoglycoside resistance gene
homologues
For the detection of aminoglycoside resistant genes, de-
generate primer sets were used which had previously been
designed and shown to amplify all known genes encoding
gentamycin-modifying enzymes and similar, but as yet un-
discovered, sequences [20]. PCRs were completed using
primer sets (MWG Eurofins, Germany) for genes belong-
ing to each group of aminoglycoside modifying enzymes
namely, acetylation, adenylation and phosphorylation
enzymes. DNA from positive controls (kindly gifted to
us from the Smalla laboratory, JKI, Braunschweig) namely
Escherichia coli S17-1 pAB2002 (aac (3)-Ia), Pseudomonas
aeruginosa 88.341 F (aac (3)-Ib), Enterobacter aerogenes
17798 VDK (aac (3)-IIa), E. coli DH5α pSCH4203 (aac
(3)-IIb), E. coli DH5α pSCH4101 (aac (3)-VIa), P. aerugi-
nosa PST-1 (aac (3)-IIIa), Acinetobacter baumannii LBL.3
(aac (6′)-Ib), P. aeruginosa F-03 (aac (6′)-IIa), E. coli DH5α
pSCH5102 (aac (6′)-IIb), E. coli CV600 pIE723 (ant (2″)-I),
E. coli DH5α pAM6306 (aph (2″)-Ic) and E. coli NC95
(aph (2″)-Id) were used as positive controls for the PCR
reactions. This ensured the specificity of the respective
primer pairs. PCRs for the detection of acetylation genes
aac (3)-I, aac (3)-II, aac (3)-III, aac (3)-VI and aac (6),
adenylation genes ant (2″)-Ia and phosphorylation genes
aph (2″)-Ic and aph (2″)-Id were completed as previously
outlined [20] (Table 1). Additionally, PCRs using primers
for the bifunctional gene aac (6″)-Ie-aph (2″) [26,27]
(which encodes enzymes responsible for high level genta-
mycin resistance, as well as concomitant resistance to
tobramycin and kanamycin) [27-31] were completed as
follows: heated lid 110°C, 94°C × 5 mins followed by
30 cycles of 94°C × 30s, 47°C × 30s, 72°C × 30s, with a
final extension step of 72°C × 10 mins and held at 4°C.
All PCRs contained 25 μl Biomix Red (Bioline, UK), 1 μl
forward primer (10pmol concentration), 1 μl reverse pri-
mer (10pmol concentration), metagenomic DNA (64 ng)
and PCR grade water (Bioline, UK), to a final volume of
50 μl. Negative controls were run for all primer sets. All
PCRs were performed in triplicate and analysed using gel
electrophoresis, as described above.
Cloning of PCR amplicons
Triplicate samples from successful PCR reactions were
pooled and cleaned using AMPure magnetic bead-based
PCR clean up kit (Beckman Coulter, UK). TOPO cloning
reactions were performed on purified PCR products using
the TOPO TA cloning kit (Invitrogen, Dublin, Ireland) tofacilitate the sequencing of individual gene fragments.
TOPO cloning reactions were then cloned into TOP10
E. coli (Invitrogen) as per the manufacturer’s instructions
and plated onto LB (Difco) containing the appropriate
antibiotic (either ampicillin 50 μg/ml or kanamycin 50 μg/
ml; Sigma Aldrich, Dublin, Ireland) to select for the pres-
ence of the cloning vector. Transformants were selected
from each TOPO cloning reaction and grown overnight in
LB broth containing the suitable selective antibiotic (either
ampicillin 50 μg/ml or kanamycin 50 μg/ml). Plasmids
were extracted from overnight samples using QIAprep
Spin Mini Prep kit (Qiagen, Sussex, UK) according to the
manufacturer’s instructions and sent for Sanger sequen-
cing (Source BioSciences, Dublin, Ireland).
Bioinformatic analysis
Following Sanger sequencing, sequence reads were analysed
using the NCBI protein database (BlastX; (http://blast.ncbi.
nlm.nih.gov/)). In the event where multiple hits occurred,
the BLAST hit which displayed greatest homology is
reported.
Results and discussion
A PCR-based approach highlights the presence of
β-lactamase gene homologues in the gut microbiota
The results of the β-lactamase-specific PCRs demonstrated
the presence and diversity of class 2 β-lactamase genes in
the gut microbiota of healthy adults (Table 2 [32]). Of the
β-lactam primers used, the primers designed to amplify
blaTEM genes yielded the greatest number of unique
sequence hits (42% of selected TOPO sub-clones gave
a unique hit). The majority of these genes exhibited a
high percentage identity with genes from various members
of the Proteobacteria including E. coli, Klebsiella, Salmon-
ella, Serratia, Vibrio parahaemolyticus and Escherichia vul-
neris. The resistance of strains of Salmonella and Serratia
to β-lactams via blaTEM genes has been noted [33-35] and
such strains have been associated with nosocomial infec-
tions [36]. In contrast, there have been relatively few studies
of blaTEM genes in Vibrio parahaemolyticus and Escheri-
chia vulneris [37,38]. The identification of genes homolo-
gous to those from Enterobacteriaceae is not surprising
given the prevalence of resistance genes among members
of this family [12]. It was notable that the blaTEM primers
also amplified genes that resembled blaTEM genes from
some more unusual sources, including two genes from
uncultured bacteria and from a Sar 86 cluster (a divergent
lineage of γ-Proteobacteria) bacteria. This approach can
thus provide an insight into possible novel/unusual sources
of resistance genes, including those that culture-based ap-
proaches would fail to detect. Such results also highlight
that had initial screening for resistant isolates been com-
pleted prior to PCR amplification of the resistance genes,
such unusual sources of resistance genes may have been
Table 2 Homologues of β-lactamase genes detected in the human gut microbiota via PCR techniques
Accession # Gene description Closest homologue E value % identity
BlaTEM
ADE18890.1 β-lactamase TEM-1 S. enterica subsp. enterica 5e-154 99
AAS46844.1 β-lactamase TEM-1 S. marcescens 2e-156 100
AEN02824.1 β-lactamase TEM-1 K. pneumoniae 3e-111 99
AEN02817.1 β-lactamase TEM-1 K. pneumoniae 1e-113 99
ACV88636.1 β-lactamase TEM-1 E. coli 2e-151 99
AEL87577.1 ES β-lactamase TEM-116 Vibrio parahaemolyticus 5e-154 99
AEQ55231.1 β-lactamase TEM-1 E. coli 1e-35 45
ABQ14376.1 β-lactamase Uncultured soil bacterium 6e-05 83
ADN79104.1 β-lactamase TEM Escherichia vulneris 1e-15 86
WP_010157942.1 β-lactamase TEM Sar 86 cluster bacterium 9e-122 83
ACI29961.1 β-lactamase TEM-1 E. coli 2e-153 99
AEQ39590.1 β-lactamase TEM-195 E. coli 5e-93 96
AAM22276.1 β-lactamase TEM-96 E. coli 7e-139 94
WP_019405145.1 β-lactamase TEM K. pneumoniae 4e-155 99
AEW28787.1 β-lactamase TEM-1 Uncultured bacterium 1e-133 100
ABY81267.1 β-lactamase E. coli 4e-156 100
AAF74292.1 ES β-lactamase E. coli 5e-155 99
AFU53026.1 KPC-2 β lactamase S. marcescens 2e-112 98
ADE18896.1 β-lactamase TEM-1 Salmonella enterica 2e-113 99
AEN02826.1 β-lactamase TEM-1 K. pneumoniae 4e-113 99
BlaROB
YP_252228.1 Hypothetical protein SH0313 S. haemolyticus 2e-33 44
BlaSHV
WP_009348253.1 Hypothetical protein HMPREF 9332 Alloprevotella rava 3e-07 56
WP_017896153.1 β-lactamase K. pneumoniae subsp. pneumoniae 0.0 99
WP_008157744.1 Hypothetical protein HMPREF 1077 Parabacteroides johnsonii 1.5 29
CAJ47138.2 β-lactamase K. pneumoniae 0.0 99
ADU15837.1 BlaSHV132 K. pneumoniae 0.0 99
AEK80394.1 β-lactamase SHV140 K. pneumoniae 0.0 99
ABS72351.1 β-lactamase SHV103 K. pneumoniae 0.0 99
AAP03063.1 β-lactamase SHV48 K. pneumoniae 0.0 99
AEG79634.1 ES β-lactamase SHV120 E. coli 99
BlaCTX-M
ABG46354.1 ES β-lactamase E. coli 3e-139 99
AEZ49563.1 β-lactamase CTX-M-1 E. coli 2e-138 99
AEZ49551.1 β-lactamase CTX-M-1 K. pneumoniae 1e-139 100
ABG46356.1 ES β-lactamase K. pneumoniae 9e-139 97
ABW06480.1 ES β lactamase CTX-M-15 K. pneumoniae 6e-51 94
AAB22638.1 β-lactamase penicillin hydrolase E. coli 9e-140 100
BAD16611.1 β-lactamase CTX-M-36 E. coli 8e-139 99
YP_003717483.1 β-lactamase E. coli 2e-139 100
ABN09669.1 β-lactamase CTX-M-61 S. enterica 2e-138 100
ESBL: extended spectrum β-lactamase. Gene names are in bold.
Fouhy et al. BMC Microbiology 2014, 14:25 Page 5 of 10
http://www.biomedcentral.com/1471-2180/14/25
Fouhy et al. BMC Microbiology 2014, 14:25 Page 6 of 10
http://www.biomedcentral.com/1471-2180/14/25overlooked. Additionally, genes encoding ESBLs, including
blaTEM-116, blaTEM-195 and blaTEM-96 amongst others, were
also identified, with their closest homologues being mem-
bers of the Proteobacteria (Table 2).
Using the blaSHV primers, multiple genes sharing hom-
ology with genes from members of the Enterobacteriaceae,
and Klebsiella and E. coli in particular were detected. In
addition, amplicons with low percentage identity to genes
from Alloprevotella rava and Parabacteroides johnsonii,
respectively, were also identified. This is again consistent
with existing research which states that Enterobacteriaceae
are the primary source of blaSHV genes [39-43]. Further-
more, the amplicons sequenced resembled various different
types of ESBL-encoding SHV genes, including blaSHV-132,
blaSHV-140 and blaSHV-48, thus again highlighting the genu-
ine degeneracy of the primers used.
Additional PCRs were completed to identify other ESBLs,
specifically CTX-M- and OXA-type β-lactamases (Table 2).
A number of different CTX-M β-lactamases were detected,
including CTX-M-1, CTX-M-15 and CTX-M-36. The fact
that many of the β-lactamase genes detected using our
approach share homology with resistance genes found in
members of the phylum Proteobacteria is not surprising
as, despite being typically less common than the Bacteroi-
detes or Firmicutes in the gut microbiota of healthy adults
[21], members of this genus have been identified as
sources of antibiotic resistance genes and have been
frequently associated with nosocomial infections and
outbreaks [36,39,44,45]. In the 1990s, TEM- and SHV-type
ESBLs were the β-lactamases most frequently observed
among Enterobacteriaceae [18]. However, more recently,
CTX-M-type ESBLs have spread rapidly and are now the
most prevalent ESBL in Enterobacteriaceae in several parts
of the world [46]. In a recent report on antibiotic resistance
threats in the USA, the Centre for Disease Control stated
that ESBL-producing Enterobacteriaceae were a serious
public health threat [47]. The report estimates that 26,000
infections and 1,700 deaths that occur each year in the
United States are attributable to ESBLs and that upwards of
140,000 health-care related Enterobacteriaceae infections
occur annually. Therefore the detection of homologues of
ESBL-encoding genes in the gut microbiota of healthy indi-
viduals is significant and provides evidence of the ubiqui-
tous nature of these resistance genes, even in the absence
of recent antibiotic exposure. With respect to the CTX-
M-type ESBLs, it is particularly notable that homologues
of the blaCTX-M-15 gene were detected, as these have
received significant attention due to their recent rapid
spread and their association with multi-drug resistant
E. coli responsible for outbreaks of antibiotic resistant
infections [48,49]. In such cases, these genes have been
found on multi-drug resistance-encoding regions of plas-
mids, thus facilitating the rapid transfer of these genes.
The presence of such genes within the gut microbiotaraises concerns that horizontal gene transfer may occur
between commensals or to bacteria passing through the
gut. If the resistance genes detected in our study are, or
were to become, mobile, it would enable the gut to act not
only as a source of resistance genes, but also as a site of
resistance gene transfer. Although outside the scope of
this study, studies investigating whether these genes are
located on or near mobile genetic elements would be
pertinent to ascertain the risk of the gut acting as a site
for horizontal gene transfer.
When the blaROB primer set was employed to detect the
presence of homologues of these ampicillin resistance-
encoding genes, all amplicons sequenced were identical
and shared 44% identity to Staphylococcus haemolyticus
blaROB gene. Finally, this study did not detect blaOXA gene
homologues in our metagenomic sample. These findings
are unexpected and may have occurred as a result of the
particular affinity of the primer sets used.
A PCR-based approach highlights the presence of
aminoglycoside resistance encoding gene homologues
in the gut microbiota
Degenerate primers were selected that amplify genes
encoding aminoglycoside modifying enzymes from each of
the enzyme modification groups, namely acetylation,
adenylation and phosphorylation [32]. When primers
were applied to detect acetylation-associated genes, it
was established that the primers designed to target aac
(3)-I, aac (3)-II, and aac (3)-III homologues did not
generate amplicons. In each of these PCR reactions the
positive controls successfully amplified, thus we are
satisfied that the lack of amplification products for our
metagenomic sample is a true result. However, a number of
distinct aac (6) and aac (3)-VI homologues were detected
and were found to resemble genes from a variety of genera,
including Acinetobacter, Pseudomonas and Enterobacter
(Table 3). The presence of aminoglycoside acetylation
genes within these genera has been noted previously
[50-53]. The detection of resistance genes resembling
those seen in A. baumannii is a concern, as many strains
of this species have been shown to exhibit multi-drug
resistance [54,55]. In addition, homologues of genes from
Collinsella and Salmonella were also detected. Primers de-
signed to amplify bifunctional aac (6′)-Ie-aph (2′) genes
were also employed. Our investigations revealed the pres-
ence of homologues of such genes, resembling those from
S. aureus, E. faecium and S. epidermidis, all of which are
known sources of these genes [27,56,57].
Homologues of aminoglycoside phosphorylation-encoding
genes were also detected using a PCR-based approach,
with both aph (2″)-Ic and aph (2″)-Id like genes being
detected. These genes shared homology with genes from
Enterococcus species, including E. faecium and E. casseli-
flavus. Aminoglycoside resistant E. faecium have received
Table 3 Homologues of aminoglycoside resistance genes detected in the human gut microbiota via PCR techniques
Accession # Gene description Closest homologue E value % identity
aac (6)
AAA25680.1 AG 6′-N-acetyltransferase Pseudomonas fluorescens 4 e-48 98
WP_006234103.1 Hypothetical protein Colaer00186 Collinsella aerofaciens 0.0 95
AAS45464.1 6′-N-acetyltransferase A. baumannii 3e-33 75
aac (6′)-Ie-aph (2″)
WP_002304968.1 Phosphotransferase E. faecium 9e-108 100
WP_001028140.1 Acetyltransferase GNAT S. aureus 1e-107 99
WP_001028143.1 Acetyltransferase GNAT S. aureus 1e-107 99
WP_010729367.1 Bifunctional AAC/APH partial sequence E. faecium 5e-106 99
AAX82584.1 Bifunctional AG modifying enzyme Enterococcus faecalis 2e-112 100
WP_002417297.1 6′ AG acetyltransferase E. faecalis 3e-111 97
AFR11868.1 Bifunctional AG 6′-N acetytransferase/2′-AG
phosphotransferases
S. epidermidis 1e-43 99
AFM29914.1 Gentamycin resistance protein Enterococcus sp. 7e-45 97
aph (2″) Id
3SG8_A Chain A crystal structure AG 2′
phosphotransferases
E. casseliflavus 1e-110 98
3N4T_A Aph2″ chain a E. casseliflavus 2e-110 99
AAT77696.1 AG modifying enzyme E. faecium 1e-68 94
Aph (2″)-Ic
3TDVA AG phosphotransferase Enterococcus gallinarum 2e-83 97
ant (2″) Ia
YP_005176240.1 AG 2′–O-adenyltransferase Pasturella mutocida 2e-97 100
WP_000314377.1 2′ AG nucleotidlytransferase A. baumannii 3e-94 99
WP_000946493.1 2′ AG A. baumannii 1e-94 99
ACJ47203.1 AG adenyltransferase E. coli 6e-94 99
ACA48663.14 AG adenyltransferase Morganella morganii 2e-96 99
aac(3)-VI
AAA16194.1 aac 3–6 Enterobacter cloacae 2e-05 77
WP_001642188.1 AG acetyltransferase S. enterica subsp enterica 2e-20 98
AG: aminoglycoside. Gene names are in bold.
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tions [58,59]. Notably, the role of mobile genetic elements
in the maintenance and dissemination of multi-drug re-
sistance in Enterococcus faecalis and E. faecium has previ-
ously been highlighted [30,60,61]. While it is not certain
that the genes identified in this study are also associated
with mobile elements, the possibility that resistance genes
could be transferred to commensals is a concern. Homo-
logues of aminoglycoside adenylation genes, ant (2″)-Ia,
were also successfully detected. These resembled genes
from Pasteurella, Acinetobacter and E. coli (Table 3), and
the findings are thus consistent with previous research
showing that these genes are most frequently detected
in Gram negative bacteria [62]. Overall, the results dem-
onstrate that the gut microbiota is a source of diverse
aminoglycoside and β-lactam resistance genes, despitehaving had no recent antibiotic exposure. If these genes are
expressed there is the potential that if antibiotic exposure
occurred, bacteria containing these resistance genes would
become the dominant component of the gut microbiota,
as has been shown in previous studies [5,63].
Conclusions
This study has highlighted the merits of applying a
PCR-based approach to detect antibiotic resistance genes
within the human gut microbiome. The results clearly
demonstrate that the human gut microbiota is a consider-
able reservoir for resistance genes. Further studies are
required to determine the exact sources of these genes and
to determine if they have the potential to become mobile.
Additionally, we have highlighted the successful application
of a PCR-based screen of a complex environment without
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http://www.biomedcentral.com/1471-2180/14/25prior isolation of resistant isolates. The possibility exists
to couple this approach with lower throughput next
generation sequencing strategies, such as that provided by
the Ion PGM 314 chip, in instances where great diversity
is likely. Our approach could also be used in conjunction
with functional screening of metagenomic libraries to
enable the detection of genes present in a complex en-
vironment at a low threshold and that may have avoided
capture in the metagenomic library, as shown in a re-
cent study [64]. Such a PCR-based approach is not being
proposed as a substitute for ultra-deep high-throughput
shotgun sequencing of metagenomic DNA, rather it is a
lower cost, more targeted, alternative which facilitates
the detection and in silico analysis of specific gene sets
of interest. Finally, while this study demonstrates that
the gut microbiota is a source of diverse resistance
genes, further studies are required to investigate the exact
sources of these genes, their expression and whether they
have the potential to become mobile. As the scientific
community continues to gain knowledge with respect to
the genetic mechanisms involved in providing resistance
to various antibiotics, the design of additional sets of de-
generate primers will be possible and will provide further
opportunities for the use of PCR to rapidly and efficiently
detect antibiotic resistance genes in complex microbial
environments, including the human gut microbiota.Availability of supporting data
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